Please login to the form below

Not currently logged in
Email:
Password:

Biovitrum

This page shows the latest Biovitrum news and features for those working in and with pharma, biotech and healthcare.

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Hopes to boost haematology franchise with lead drug Doptelet. Dova Pharmaceuticals is set to be acquired by Swedish Orphan Biovitrum AB (Sobi) for up to $915m, dependent on the regulatory approval

Latest news

More from news
Approximately 4 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    Orphan Biovitrum) a company that, as its name suggests, is entirely dedicated to rare conditions.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    49. †Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum.  Development, supply and commercialisation. Xiapex (collagenase clostridium histolyticum) (approved)  .  40. All deals are worldwide unless otherwise noted – see below:.   .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...